Himanshu Bhatt

Dr. Himanshu Bhatt


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

9 November 2022 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
EBElfa Beaven
Elfa Beaven
RKRaj Kumar
Raj Kumar
HBHimanshu Bhatt
Himanshu Bhatt
SEStephanie V. Esquivel
Stephanie V. Esquivel
MNMd Nurunnabi
Md Nurunnabi
Fibrosis has been shown to develop in individuals with underlying health conditions, especially chronic inflammatory diseases.

10 April 2014 in Journal of Pharmaceutics
Verified
Journal Article
Open access
PDF file
HBHimanshu Bhatt
Himanshu Bhatt
BNBhargavi Naik
Bhargavi Naik
ADAbhay Dharamsi
Abhay Dharamsi
The purpose of the research was to present Budesonide (BUD) as a novel formulation showing improved aqueous solubility, which may decrease variability in Cmax⁡ and Tmax⁡ found in inflammatory bowel disease (IBD) patients, and drug targeting to colon. To improve aqueous solubility, solid dispersion (SD) of the BUD with poloxamer 188 was prepared by melting method. Physical characterization of solid dispersion was performed. The SD was used to prepare tablet equivalent to 9 mg of BUD. The tablet was coated with enteric polymers Eudragit S100 and Eudragit L100 to target colon. The ratio of polymers and percentage coating was optimized using statistical design. Variables studied in design were ratio of enteric polymers and the effect of percentage coating on in vitro drug release. Dissolution at different pH showed that drug release in colon could be modified by optimizing the ratio of polymers and percentage coating. The dissolution data showed that the percentage coating and ratio of polymers are very important to get lag time and optimum formulation. The optimized batch from statistical design was kept under accelerated condition for three months. After accelerated stability study, there was no significant change in the drug release.

7 May 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Ana Sofia SerraAna Sofia Serra
Ana Sofia Serra
DEDalinda Eusébio
Dalinda Eusébio
ANAna Raquel Neves
Ana Raquel Neves
TATânia Cristina de Oliveira Albuqerque
Tânia Cristina de Oliveira Albuqerque
HBHimanshu Bhatt
Himanshu Bhatt
Ângela SousaÂngela Sousa
Ângela Sousa
DNA vaccines still represent an emergent area of research, giving rise to continuous progress towards several biomedicine demands. The formulation of delivery systems to specifically target mannose receptors, which are overexpressed on antigen presenting cells (APCs), is considered a suitable strategy to improve the DNA vaccine immunogenicity. The present study developed binary and ternary carriers, based on polyethylenimine (PEI), octa-arginine peptide (R8), and mannose ligands, to specifically deliver a minicircle DNA (mcDNA) vaccine to APCs. Systems were prepared at various nitrogen to phosphate group (N/P) ratios and characterized in terms of their morphology, size, surface charge, and complexation capacity. In vitro studies were conducted to assess the biocompatibility, cell internalization ability, and gene expression of formulated carriers. The high charge density and condensing capacity of both PEI and R8 enhance the interaction with the mcDNA, leading to the formation of smaller particles. The addition of PEI polymer to the R8-mannose/mcDNA binary system reduces the size and increases the zeta potential and system stability. Confocal microscopy studies confirmed intracellular localization of targeting systems, resulting in sustained mcDNA uptake. Furthermore, the efficiency of in vitro transfection can be influenced by the presence of R8-mannose, with great implications for gene expression. R8-mannose/PEI/mcDNA ternary systems can be considered valuable tools to instigate further research, aiming for advances in the DNA vaccine field.